FDA Cuts Red Tape for Cancer Gene Tests, Patients Rejoice
Published Date: 11/25/2025
Proposed Rule
Summary
The FDA wants to change the rules for certain cancer-related genetic test systems, making them easier to get approved by moving them from a strict Class III to a more flexible Class II category. This affects companies making these tests and could speed up how quickly patients get access to important cancer treatments. Comments on this change are open until January 26, 2026, so now’s the time to speak up!
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Class III → Class II: 510(k) Instead of PMA
The FDA proposes to reclassify certain nucleic acid-based oncology test systems (product codes OWD, PJG, PQP, and SFL) from Class III (PMA) to Class II (special controls). If finalized, manufacturers would no longer need a Premarket Approval (PMA) but must submit a premarket notification (510(k)) before marketing these devices.
Faster Patient Access to Cancer Tests
FDA says reclassifying these oncology nucleic acid-based test systems to Class II and using the 510(k) pathway may result in shorter premarket review timelines and enable more manufacturers to develop these tests, which could provide more timely access to tests that guide cancer treatment decisions.
Use of Predetermined Change Control Plans
Manufacturers may use FDA-authorized predetermined change control plans (PCCPs) to implement future modifications described in an approved PCCP without submitting a new 510(k) or PMA supplement for each change, under section 515C of the FD&C Act (FDORA, enacted December 29, 2022).
Prescription IVD Labeling Requirement
If reclassified to Class II, these devices will be identified as prescription in vitro diagnostics (IVDs) and will be subject to prescription labeling requirements for IVD products (see 21 CFR 809.10(a)(4) and (b)(5)(ii)).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-20949 — Modification of Class E Airspace; Driggs/Reed Memorial Airport, Driggs, ID
The FAA wants to change the airspace rules around Driggs/Reed Memorial Airport in Idaho to make flying safer and easier for pilots using instruments. This update mainly affects pilots and air traffic controllers and won’t cost anyone extra. If you have thoughts, you’ve got until January 9, 2026, to speak up!
Next: 2025-21087 — Enhanced Transparency and Public Accountability of the Supervisory Stress Test Models and Scenarios; Modifications to the Capital Planning and Stress Capital Buffer Requirement Rule, Enhanced Prudential Standards Rule, and Regulation LL; Extension of Comment Period
The Federal Reserve is making its bank stress tests clearer and easier to understand for everyone. Banks will see some changes in how these tests work starting in 2026, helping keep our money safe. You’ve got until February 21, 2026, to share your thoughts on these updates!